Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SCoTMOF

Financiado

Cerrado

Combined Chemo and Radiotherapies by Controlling the Surface Chemistry of Trunc...

Combined Chemo and Radiotherapies by Controlling the Surface Chemistry of Truncated Metal Organic Framework Nanoparticles Cancers are the leading cause of death in the developed world, with populations facing a 30% chance of developing the disease by the age of 75. As part of a concerted effort to open up new treatments and improve patients’ experien... ver más

31/08/2022

UNIVERSITY OF GLAS...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-08-31

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY OF GLASGOW

1.49M€ | Lider

FLUITECNIK, S.A.

1.78M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GateMOF Molecular gated Eco-MOFs for anti-cancer drug delivery 165K€ Cerrado

NanoBioMOFs Nanoscale Metal Organic Frameworks for Biomedical Applicatio... 169K€ Cerrado

NanoMOFdeli Design of NanoMOFs Capsules for Drug Delivery and Bioimaging... 2M€ Cerrado

CTQ2017-90050-R GLICO-NANOSISTEMAS MULTIVALENTES BASADOS EN METALES NOBLES Y... 80K€ Cerrado

CTQ2013-48380-R GLICO-NANOSISTEMAS BASADOS EN ESTRUCTURAS POROSAS METAL-ORGA... 104K€ Cerrado

PID2021-128249NB-I00 MODIFICACION NO-COVALENTE DE LA SUPERFICIE DE REDES METAL-OR... 121K€ Cerrado

Duración del proyecto: 76 meses Fecha Inicio: 2016-04-28
Fecha Fin: 2022-08-31

Líder del proyecto

UNIVERSITY OF GLASGOW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancers are the leading cause of death in the developed world, with populations facing a 30% chance of developing the disease by the age of 75. As part of a concerted effort to open up new treatments and improve patients’ experiences with existing ones, the concept of drug delivery – using non-toxic carriers to transport medicines directly to the location of disease – has emerged. Metal-organic frameworks (MOFs), porous materials comprised of organic linkers and metal joints, show considerable promise as drug delivery vectors due to their high storage capacities, amenability to functionalization and the ability to prepare entirely non-toxic nanoparticulate derivatives. This proposal will use the PI’s expertise in advanced MOF synthetic methods to facilitate dramatic technological breakthroughs through unprecedented control of MOF self-assembly and surface chemistry. Management of MOF surface chemistry will allow installation of stimuli responsive release mechanisms and offer control over the trapping and release of cargo within MOFs, ensuring drugs are released only at the site of disease in the body. Surface incorporation of sophisticated biotargeting units such as peptides and aptamers will facilitate selective uptake of the MOFs by diseased tissues only. Rapid clean microwave syntheses will allow metal radionuclides to be incorporated for PET imaging, offering a novel alternative to traditional chelates. Comprehensive in vitro and in vivo testing will ensure that this multidisciplinary streamlining of materials, supramolecular and medicinal chemistries with the biosciences will generate highly efficient theranostic devices, offering more efficient, targeted drug delivery to improve treatment efficiency, mitigate side effects and open up new therapeutic avenues such as siRNA delivery. The fundamental advances required to generate these novel materials will also impact across the many applications of MOFs, from molecular storage and separations to catalysis.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores